Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 25:361:k1315.
doi: 10.1136/bmj.k1315.

Anticholinergic drugs and risk of dementia: case-control study

Kathryn Richardson  1 , Chris Fox  2 , Ian Maidment  3 , Nicholas Steel  2 , Yoon K Loke  2 , Antony Arthur  1 , Phyo K Myint  4 , Carlota M Grossi  1 , Katharina Mattishent  2 , Kathleen Bennett  5 , Noll L Campbell  6 , Malaz Boustani  7 , Louise Robinson  8 , Carol Brayne  9 , Fiona E Matthews  10 , George M Savva  1
Affiliations

Anticholinergic drugs and risk of dementia: case-control study

Kathryn Richardson et al. BMJ. .

Erratum in

Abstract

Objectives: To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia.

Design: Case-control study.

Setting: General practices in the UK contributing to the Clinical Practice Research Datalink.

Participants: 40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia.

Interventions: Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia.

Main outcome measures: Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates.

Results: 14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis.

Conclusions: A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure.

Trial registration: Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work beyond the Alzheimer's Society grant. IM reports personal fees for guest lectures from Astellas Pharmaceuticals. YL reports personal fees from Thame Pharmaceuticals. NC and CF report grants and personal fees from Astellas Pharmaceuticals.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017;390:2673-734. 10.1016/S0140-6736(17)31363-6. - DOI - PubMed
    1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study Age, neuropathology, and dementia. N Engl J Med 2009;360:2302-9. 10.1056/NEJMoa0806142. - DOI - PubMed
    1. White LR, Edland SD, Hemmy LS, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology 2016;86:1000-8. 10.1212/WNL.0000000000002480. - DOI - PMC - PubMed
    1. Matthews FE, Arthur A, Barnes LE, et al. Medical Research Council Cognitive Function and Ageing Collaboration A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013;382:1405-12. 10.1016/S0140-6736(13)61570-6. - DOI - PMC - PubMed
    1. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016;15:455-532. 10.1016/S1474-4422(16)00062-4. - DOI - PubMed

Substances